Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYSA-6: KYV-101 versus standard immunosuppressive therapy in generalized myasthenia gravis
2023-509892-17-00Phase 3Authorised
- Sponsor
- Kyverna Therapeutics
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in myasthenia gravis (MG) comparing KYV-101 with Ongoing standard-of-care immunosuppressive therapy (2 arms). Planned start Jul 2024; status: authorised.
02
Drugs
mivocabtagene autoleucel
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-509892-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509892-17-00.